• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Brexpiprazole
    1 Drug classified under this active ingredient


    All the Active Ingredient Drugs

    REXULTI
    Lundbeck
    RX
    not in the basket chart
    REXULTI

    Atypical Antipsychotic. Brexpiprazole 0.5, 1, 2, 3, 4 mg.
    F.C. TABS.: 28. Adjunctive tmt. of Major Depress. Disor.: The recom. start. dosage for brexipiprazole as adjunctive tmt. is 0.5 mg or 1 mg×1/d, orally with/without food.
    Titrate to 1 mg once dly,. then up to the target dosage of 2 mg once dly. Dosage incr. should occur at wkly. intervals based on the pt’s. clinical response and tolerability. The max. recomm. dly. dosage is 3 mg. Periodically reassess to determine the continued need and appropriate dosage for tmt.
    Tmt. of Schizophrenia: The recom. start. dosage for Brexipiprazole is 1 mg×1/d. on Days 1-4, taken orally with/without food.
    The recom. target brexipiprazole dosage is 2 mg-4 mg×1/d. Titrate to 2 mg×1/d once dly. on Day 5 through Day 7, then to 4 mg on Day 8 based on the pts. clinical response and tolerability. The max. recom. dly. dosage is 4 mg.
    Dosage Adjustm. for Hepatic Impair.: For pts. with moderate to severe hepatic impair. (Child-Pugh score ≥7), the max. recom. dosage is 2 mg×1/d for pts. with MDD, and 3 mg×1/d for pts. with schizophrenia.
    Dosage Adjust. for Renal Impair.: For pts. with moderate, severe or end-stage renal impair. (CLcr<60 mL/minute), the max. recom. dosage is 2 mg×1/d for pts. with MDD and 3 mg×1/d for pts. with schizophrenia.
    As adjunct. ther. to antidepressants for the tmt. of major depressive disorder (MDD).
    For tmt. of schizophrenia.
    C/I: Patients with a known hypersensitivity to brexpiprazole or any of its component.
    Reactions have included rash, facial swelling, urticaria, and anaphylaxis.

    CLOSE